Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.

Responsive image


Tetrahydrocannabivarin

Tetrahydrocannabivarin
Clinical data
Routes of
administration
Oral, smoked, inhaled
ATC code
  • None
Legal status
Legal status
  • US: Unscheduled
  • Also legal in UK, Canada and Netherlands
Identifiers
  • 6,6,9-Trimethyl-3-propyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H26O2
Molar mass286.415 g·mol−1
3D model (JSmol)
  • CCCC1=CC2=C(C3C=C(CCC3C(O2)(C)C)C)C(=C1)O
  • InChI=1S/C19H26O2/c1-5-6-13-10-16(20)18-14-9-12(2)7-8-15(14)19(3,4)21-17(18)11-13/h9-11,14-15,20H,5-8H2,1-4H3/t14-,15-/m1/s1 checkY
  • Key:ZROLHBHDLIHEMS-HUUCEWRRSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Tetrahydrocannabivarin (THCV, THV, O-4394, GWP42004) is a homologue of tetrahydrocannabinol (THC) having a propyl (3-carbon) side chain instead of pentyl (5-carbon), making it non-psychoactive in lower doses. It has been shown to exhibit neuroprotective activity, appetite suppression, glycemic control and reduced side effects compared to THC, making it a potential treatment for management of obesity and diabetes.[1] THCV was studied by Roger Adams as early as 1942.[2]

  1. ^ Abioye A, Ayodele O, Marinkovic A, Patidar R, Akinwekomi A, Sanyaolu A (January 2020). "Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes". Journal of Cannabis Research. 2 (1): 6. doi:10.1186/s42238-020-0016-7. PMC 7819335. PMID 33526143.
  2. ^ Adams R, Loewe S, Smith CM, McPhee WD (1942). "Tetrahydrocannabinol Homologs and Analogs with Marihuana Activity. XIII1". Journal of the American Chemical Society. 64 (3): 694–697. doi:10.1021/ja01255a061.

Previous Page Next Page